Literature DB >> 19548351

Serotonergic neurotoxic thioether metabolites of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): synthesis, isolation, and characterization of diastereoisomers.

Nieves Pizarro1, Rafael de la Torre, Jesús Joglar, Noriko Okumura, Ximena Perfetti, Serrine S Lau, Terrence J Monks.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a synthetic recreational drug of abuse that produces long-term toxicity associated with the degeneration of serotonergic nerve terminals. In various animal models, direct administration of MDMA into the brain fails to reproduce the serotonergic neurotoxicity, implying a requirement for the systemic metabolism and bioactivation of MDMA. Catechol-thioether metabolites of MDMA, formed via oxidation of 3,4-dihydroxymethamphetamine and 3,4-dihydroxyamphetamine (HHMA and HHA) and subsequent conjugation with glutathione (GSH), are selective serotonergic neurotoxicants when administered directly into brain. Moreover, following systemic administration of MDMA, the thioether adducts are present in rat brain dialysate. MDMA contains a stereogenic center and is consumed as a racemate. Interestingly, different pharmacological properties have been attributed to the two enantiomers, (S)-MDMA being the most active in the central nervous system and responsible for the entactogenic effects, and most likely also for the neurodegeneration. The present study focused on the synthesis and stereochemical analysis of the neurotoxic MDMA thioether metabolites, 5-(glutathion-S-yl)-HHMA, 5-(N-acetylcystein-S-yl)-HHMA, 2,5-bis-(glutathion-S-yl)-HHMA, and 2,5-bis-(N-acetylcystein-S-yl)-HHMA. Both enzymatic and electrochemical syntheses were explored, and methodologies for analytical and semipreparative diastereoisomeric separation of MDMA thioether conjugates by HPLC-CEAS and HPLC-UV, respectively, were developed. Synthesis, diastereoisomeric separation, and unequivocal identification of the thioether conjugates of MDMA provide the chemical tools necessary for appropriate toxicological and metabolic studies on MDMA metabolites contributing to its neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19548351      PMCID: PMC4075178          DOI: 10.1021/tx8002017

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  41 in total

1.  In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector.

Authors:  H K Lim; R L Foltz
Journal:  Chem Res Toxicol       Date:  1988 Nov-Dec       Impact factor: 3.739

2.  Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons.

Authors:  C J Schmidt; V L Taylor
Journal:  Eur J Pharmacol       Date:  1988-10-26       Impact factor: 4.432

3.  Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users.

Authors:  U D McCann; G A Ricaurte
Journal:  J Clin Psychopharmacol       Date:  1991-10       Impact factor: 3.153

4.  Irreversible inhibition of rat glutathione S-transferase 1-1 by quinones and their glutathione conjugates. Structure-activity relationship and mechanism.

Authors:  B van Ommen; J H Ploemen; J J Bogaards; T J Monks; S S Gau; P J van Bladeren
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

5.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

6.  Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA).

Authors:  J M Paris; K A Cunningham
Journal:  Brain Res Bull       Date:  1992-01       Impact factor: 4.077

7.  Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine].

Authors:  Z Y Zhao; N Castagnoli; G A Ricaurte; T Steele; M Martello
Journal:  Chem Res Toxicol       Date:  1992 Jan-Feb       Impact factor: 3.739

8.  Transformation of dopamine and alpha-methyldopamine by NG108-15 cells: formation of thiol adducts.

Authors:  N Patel; Y Kumagai; S E Unger; J M Fukuto; A K Cho
Journal:  Chem Res Toxicol       Date:  1991 Jul-Aug       Impact factor: 3.739

9.  Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration.

Authors:  G A Ricaurte; L E DeLanney; I Irwin; J W Langston
Journal:  Brain Res       Date:  1988-04-12       Impact factor: 3.252

10.  Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct.

Authors:  M Hiramatsu; Y Kumagai; S E Unger; A K Cho
Journal:  J Pharmacol Exp Ther       Date:  1990-08       Impact factor: 4.030

View more
  4 in total

1.  Synthesis and neurotoxicity profile of 2,4,5-trihydroxymethamphetamine and its 6-(N-acetylcystein-S-yl) conjugate.

Authors:  Anne Neudörffer; Melanie Mueller; Claire-Marie Martinez; Annis Mechan; Una McCann; George A Ricaurte; Martine Largeron
Journal:  Chem Res Toxicol       Date:  2011-05-18       Impact factor: 3.739

2.  Separation and detection of D-/L-serine by conventional HPLC.

Authors:  Hiroki Shikanai; Kazuko Ikimura; Momoko Miura; Tsugumi Shindo; Akane Watarai; Takeshi Izumi
Journal:  MethodsX       Date:  2022-06-17

3.  Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Authors:  Melanie Mueller; Jie Yuan; Anne Felim; Anne Neudörffer; Frank T Peters; Hans H Maurer; Una D McCann; Martine Largeron; George A Ricaurte
Journal:  Drug Metab Dispos       Date:  2009-07-23       Impact factor: 3.922

4.  Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).

Authors:  Ricardo Pardo-Lozano; Magí Farré; Samanta Yubero-Lahoz; Brian O'Mathúna; Marta Torrens; Cristina Mustata; Clara Pérez-Mañá; Klaus Langohr; Elisabet Cuyàs; Marcel lí Carbó; Rafael de la Torre
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.